Multiple sclerosis trials in Germany

In Germany 39 Also abroad 503

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Where
Aachen, Amberg, Arnsdorf, Aschaffenburg, Bad Soden, Bamberg, Berg, Berlin, Bochum, Bogen, Buchholz, Celle, Chemnitz, Cologne, Dortmund, Düsseldorf, Eltville, Erbach/Odenwald, Erlangen, Essen, Forchheim, Frankfurt, Freiburg im Breisgau, Füssen, Giessen, Gladenbach, Günzburg, Halle, Hamburg, Hanover, Hennigsdorf, Herford, Hettingen, Ibbenbueren, Isselburg, Jena, Kiel, Leipzig, Lübeck, Magdeburg, Mannheim, Marburg, Meerbusch, Minden, München, Münster, Neuburg am Inn, Neuruppin, Neu-Ulm, Nuremberg, Öhringen, Osnabrück, Pforzheim, Quakenbrück, Regensburg, Remscheid, Rülzheim, Schwetzingen, Siegen, Singen, Sinsheim, Steglitz, Stuttgart, Sundern, Tübingen, Ulm, Unterhaching, Weil der Stadt, Wolfratshausen, Zwickau
Age
18 years and over
People
842 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06780150
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Bad Homburg, Bayreuth, Boeblingen, Dresden, Essen, Hamburg, Leipzig, Mainz, Neuburgan der Donau, Trier, Ulm
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Bad Homburg, Bayreuth, Erbach, Essen, Greifswald, Jena, Leipzig, Mainz, Muenster, Potsdam, Regensburg, Trier, Ulm, Wiesbaden
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
Where
Bielefeld, Bochum, Dresden, Jena, Kassel, Muenster, Siegen, Wuerzburg
Age
18 years and over
People
100 worldwide
Run by
Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Bochum, Dresden, Duesseldorf, Leipzig, Ulm
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 3Taking people
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Where
Bremen, Ulm, Wiesbaden
Age
18 years and over
People
500 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Where
Bielefeld, Bochum, Dresden, Essen, Jena, Kassel, Meisenheim, Münster, Siegen, Würzburg
Age
18 years to 70 years
People
200 worldwide
Run by
Celgene
See details and how to joinNCT06782490
No phaseNot yet taking people in Germany
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
Where
Ulm
Age
18 years to 70 years
People
100 worldwide
Run by
Otto Bock Healthcare Products GmbH
See details and how to joinNCT07897760
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Berlin, Bochum, Erbach, Essen, Greifswald, Heidelberg, Marburg, Muenster, Regensburg, Ulm
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Cologne, Dresden, Duesseldorf, Erbach, Greifswald, Hamburg
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Dresden, Leipzig, Unterhaching
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 2Not yet taking people in Germany
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Where
Datteln, Dresden
Age
10 years to 17 years
People
25 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Cottbus, Erbach im Odenwald, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle, Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tübingen, Ulm, Unterhaching, Wiesbaden
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Berlin, Bielefeld, Bochum, Boeblingen, Dresden, Duesseldorf, Erbach, Essen, Giessen, Jena, Leipzig, Muenster, Ulm
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Berlin, Bochum, Bonn, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim, Muenster, Munich, Tuebingen, Ulm
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Bochum, Freiburg im Breisgau, Goettingen
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
Phase 1/2Taking people
MB-CART2019.1 in refractory MS
Where
Berlin, Hamburg
Age
18 years and over
People
25
Run by
Miltenyi Biomedicine GmbH
See details and how to join2024-517601-82-00 · EU 2024-517601-82-00
No phaseEnrolling by invitation
MS-Related Disability Worsening and Thalamic Volume Loss
Where
Dresden, Multiple Locations
Age
18 years to 55 years
People
2,400
Run by
Jung Diagnostics GmbH
See details and how to joinNCT07753928
Phase 1Taking people
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Where
Leipzig, Magdeburg, Würzburg
Age
18 years to 60 years
People
24 worldwide
Run by
AstraZeneca
See details and how to joinNCT07224373
Phase 1/2Not yet taking people in Germany
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Where
Tuebingen
Age
18 years and over
People
36
Run by
Universitaetsklinikum Tuebingen AöR
See details and how to join2024-519491-60-00 · EU 2024-519491-60-00
No phaseTaking people
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Where
Bochum
People
908 worldwide
Run by
Biogen
See details and how to joinNCT05658497
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Cottbus, Erbach, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle (saale), Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tuebingen, Ulm, Unterhaching, Wiesbaden, Wuerzburg
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
No phaseTaking people
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Where
Aalen, Albstadt, Altenburg, Altenholz, Altmark, Alzey, Bad Homburg, Bamberg, Bayreuth, Bergneustadt, Berlin, Böblingen, Bochum, Bogen, Bonn, Braunschweig, Bremen, Chemnitz, Coburg, Cologne, Crailsheim, Dessau, Dillingen an der Donau, Dillingen Saar, Dortmund, Dresden, Duisburg, Düsseldorf, Eisleben Lutherstadt, Eltville, Erbach im Odenwald, Erfurt, Erlangen, Essen, Falkensee, Frankfurt am Main, Fulda, Gelsenkirchen, Giessen, Gladenbach, Görlitz, Hagen, Halle, Hamburg, Hanover, Hettingen, Höxter, Ingelheim, Itzehoe, Jena, Kaiserslautern, Karlsruhe, Leipzig, Lünen, Magdeburg, Mannheim, Marburg, Meerbusch, Merzig, Mettmann, Minden, Montabaur, Mühlhausen, Mülheim, München, Munich, Münster, Nagold, Neuburg A.d. Donau, Neuruppin, Nuremberg, Oer-Erkenschwick, Oldenburg, Osnabrück, Pforzheim, Potsdam, Regensburg, Remscheid, Rostock, Rüdersdorf, Rülzheim, Saarlouis, Salzatal, Schiltach, Schneverdingen, Schwäbisch Hall, Schwetzingen, Siegen, Sinsheim, Stadtroda, Stuttgart, Tirschenreuth, Trier, Tübingen, Unterhaching, Untermeitingen, Velbert, Weil der Stadt, Wildeshausen, Wolfratshausen
Age
18 years to 100 years
People
800
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05344469
Phase 1Not yet taking people in Germany
Immune Cell Therapy for People with Early, Active Multiple Sclerosis
Where
Hanover
Age
18 years and over
People
10
Run by
Medizinische Hochschule Hannover
See details and how to join2025-522409-39-00 · EU 2025-522409-39-00
Phase 1/2Taking people
MB-CART2019.1 in Refractory Multiple Sclerosis
Where
Berlin
Age
18 years to 55 years
People
26
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT07178431